Biotechnology Assets (041) Stock Overview
Develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
041 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Biotechnology Assets, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.21 |
| 52 Week High | €0.52 |
| 52 Week Low | €0.11 |
| Beta | 2.1 |
| 1 Month Change | 16.90% |
| 3 Month Change | 33.54% |
| 1 Year Change | -6.22% |
| 3 Year Change | -53.11% |
| 5 Year Change | -71.87% |
| Change since IPO | -89.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 041 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.8% | -1.6% | -3.8% |
| 1Y | -6.2% | -7.1% | -5.1% |
Return vs Industry: 041 matched the German Biotechs industry which returned -7.1% over the past year.
Return vs Market: 041 underperformed the German Market which returned -5.1% over the past year.
Price Volatility
| 041 volatility | |
|---|---|
| 041 Average Weekly Movement | 24.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 041's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 041's weekly volatility has decreased from 38% to 24% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 30 | n/a | www.biatgroup.com |
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VACC-ZERA technology, a tool to generate recombinant proteins in microparticles suited for therapeutic and prophylactic adjuvant free vaccines administered as DNA vaccines; and CLICK’N CUT, a tool to obtain tag-less proteins in a one-step process based on intein affinity, as well as Zebrafish assays. The company is based in Cádiz, Spain.
Biotechnology Assets, S.A. Fundamentals Summary
| 041 fundamental statistics | |
|---|---|
| Market cap | €16.49m |
| Earnings (TTM) | -€2.08m |
| Revenue (TTM) | €3.05m |
Is 041 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 041 income statement (TTM) | |
|---|---|
| Revenue | €3.05m |
| Cost of Revenue | €291.56k |
| Gross Profit | €2.76m |
| Other Expenses | €4.84m |
| Earnings | -€2.08m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 90.45% |
| Net Profit Margin | -68.10% |
| Debt/Equity Ratio | 33.2% |
How did 041 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/22 12:46 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biotechnology Assets, S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pooya Hemami | Edison Investment Research |
| Iñigo Recio Pascual | GVC Gaesco Valores |